Recently Viewed

News Announcement

Strides Pharma Science: Announcement under Regulation 30 (LODR)-Press Release / Media Release

29-Jul-2025 Follow Value Research Online on Google download pdfDownload PDF Strides Pharma

Strides Delivers a strong Q1 FY 2026 with Rs.11 197 million Revenue Rs. 2 181 million EBITDA and Rs. 1 140 million Operational PAT.

Ask Value Research aks value research information

No question is too small. Share your queries on personal finance, mutual funds, or stocks and let us simplify things for you.

Mutual Fund Insight turns 24! 🎉 Get 2 FREE anniversary guides: The Right SIP + The Big Funds